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Background. There is strong evidence that Th1 cytokines are
essential for disease in murine models of lupus. Interleukin-12
(IL-12) is essential for Th1 cell differentiation and induces inter-
feron- (IFN-) production. Paradoxically, it has been suggested
that an IL-12 defect drives the pathogenesis of lupus, although
its precise role remains unclear. We investigated the role of
IL-12 for lupus-like disease induced by pristane. IL-12p35–
deficient (/) and control (/) BALB/c mice were treated
with pristane or phosphate-buffered saline (PBS).
Methods. Proteinuria was measured and renal pathology
evaluated 10 months after treatment. Sera were analyzed for
autoantibodies and total immunoglobulin levels. Cytokine ex-
pression and production was analyzed.
Results. Pristane induced nephritogenic autoantibodies and
renal immunoglobulin and complement deposition in both
IL-12 / and / mice. However, proliferative pathology
and proteinuria were absent in IL-12/ mice, whereas pris-
tane induced severe nephritis in one third of the / mice.
As expected, cytokine balance was skewed toward a Th2 re-
sponse in pristane-treated IL-12 / mice.
Conclusion. These data indicate that renal immune complex
deposition can occur in the absence of IL-12p35, but that struc-
tural renal damage requires the presence of IL-12p35 or media-
tors induced by this molecule, such as IFN-. In contrast to
the abrogation of nephritogenic autoantibodies by the lack of
IFN-, such antibodies are induced by pristane in IL-12p35–
deficient mice. Absence of structural renal disease, despite the
presence of nephritogenic autoantibodies in pristane-treated
IL-12/ mice, indicates that antibody deposition alone is not
sufficient for the development of lupus nephritis in this model.
Lupus nephritis (LN) is a major contributor to morbid-
ity and mortality in systemic lupus erythematosus (SLE).
It is generally considered to be mediated by the glomeru-
lar deposition of immune complexes, initiating a cascade
of inflammatory events and ultimately leading to tissue
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damage. Certain autoantibodies, in particular, anti-DNA/
chromatin, are believed to be directly involved in the
pathogenesis of LN [1]. Nevertheless, even very high levels
of these autoantibodies do not obligatorily result in the
development of LN, and other events, such as those
mediated by Fc receptor signaling [2], play an essential
role for the induction of nephritis. Although there is a
substantial body of evidence linking the development of
disease in SLE to Th1 cytokines [3–7], the prevailing
paradigm remains that SLE is a Th2 cytokine–driven
disease. In particular, it has been suggested that an in-
terleukin-12 (IL-12) defect and relative abundance of
Th2 cytokines is integral to the pathogenesis of both
murine [8] and human lupus [9, 10].
Interleukin-12 is a 70 kD (p70) heterodimer composed
of two disulfide-linked chains of 35 kD (p35) and 40 kD
(p40), both of which are required for biological activity
[11]. In conjunction with IL-18, IL-12 strongly promotes
differentiation of naı¨ve T cells into Th1 cells. IL-12 is
produced mainly by antigen-presenting cells (APC), such
as macrophages and dendritic cells. Mice lacking IL-12
have a relative defect but are not entirely devoid of Th1
responses [12]. In the absence of IL-12, interferon-
(IFN-) production can be induced through IL-18 signal-
ing [13], although this process is thought to require the
presence of other cytokines, such as IL-2 [14].
To further define the role of IL-12 in SLE we induced
lupus-like disease in IL-12p35–deficient (/) mice with
the hydrocarbon oil pristane [6]. Lupus-like nephritis is
induced by pristane in about one third of BALB/c mice
after intraperitoneal administration, akin to the frequency
of nephritis in humans with SLE [15]. We show here
that IL-12p35 is essential for the development of struc-
tural renal damage induced by pristane. However, im-
mune complex deposits and nephritogenic autoantibod-
ies were induced in both IL-12–deficient mice and control
mice. These results further support the idea that LN is
Th1 mediated and argue that nephritogenic antibodies
alone are insufficient to generate nephritis in pristane-
induced lupus.
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METHODS
Mice
Female BALB/c J IL-12p35 / mice and age-/sex-
matched control mice (/) (Jackson Laboratory, Bar
Harbor, ME, USA), aged 10 to 12 weeks, housed under
specific pathogen-free (SPF) conditions, were injected
once intraperitoneally with either 0.5 mL of pristane (2,
6, 10, 14-tetramethylpentadecane, Sigma Chemical Co.,
St. Louis, MO, USA) or an equal volume of phosphate-
buffered saline (PBS) [6]. Serum samples were collected
from a limited number of animals from the tail vein before
treatment, 2 weeks later, and then at 1-month intervals.
At 10 months, mice were euthanized and kidneys and
spleens were removed. Proteinuria was measured at 10
months with Albustix (Bayer, Elkhart, IN, USA). Only
values 3 (300 mg/dL) were graded as abnormal.
Renal pathology
All samples were evaluated by a single renal patholo-
gist (B.P.C.) in a blinded manner as previously reported
[16]. For light microscopy (LM), tissue was fixed in 4%
paraformaldehyde and 3m paraffin sections were stained
with hematoxylin and eosin (H&E) and periodic acid-
Schiff (PAS). Mice were scored as having glomerulo-
nephritis only when 50% of their glomeruli showed a
qualitative (segmental and/or global mesangial, or prolif-
erative) lesion on multiple sections.
For immunofluorescence (IF), tissue was embedded
in OCT compound (Sakura, Japan) and 4 m unfixed
frozen sections were stained with 1:20 fluoroscein isothio-
cyanate (FITC)-conjugated goat anti-mouse immuno-
globulin (Ig) G1, 2a, 2b, or 3, or IgM (Southern Biotech-
nology, Birmingham, AL, USA), or with rabbit anti-mouse
C3 (Cappel, Durham, NC, USA). Glomerular stain-
ing was graded according to intensity on a 0 to 4 scale
(0, no staining, 4, maximum intensity staining) and the
pattern of staining (predominantly mesangial vs. capil-
lary) was recorded. Background was defined as the strong-
est level of staining observed in PBS-treated / mice
and only staining above background was considered pos-
itive.
Immunoprecipitation
Autoantibodies to cellular proteins were analyzed by
immunoprecipitation of [35S] methionine-labeled cell ex-
tract from K562 (human erythroleukemia) cells, as pre-
viously described [6]. Specificity of autoantibodies was
confirmed using murine prototype sera for nRNP/Sm
and Su.
ELISA
Sera were tested for anti-nRNP/Sm and anti-chroma-
tin autoantibodies as previously described. For the anti-
nRNP/Sm enzyme-linked immunosorbent assay (ELISA)
[6], sera were tested at 1:500 dilution and Y2 culture
supernatant served as standard (IgG2a anti-Sm-B  D
mAb). Alkaline phosphatase–conjugated goat anti-mouse
IgG (1:1000 dilution, Southern Biotechnology) was used
as second antibody.
For the anti-chromatin ELISA [17] sera were diluted
1:500 and high titer–positive MRL/lpr serum served as
standard. Binding was detected using alkaline phospha-
tase–conjugated goat anti-mouse IgG (Southern Bio-
technology). The cutoff for positive was the mean  3
standard deviation (SD) of PBS-treated / mice for
each time point.
For the anti-dsDNA ELISA, wells of microtiter plates
(Nunc Maxisorp; Nunc, Naperville, IL, USA) were coated
with 50 L of 20 g/mL plasmid DNA and incubated
with sera at a dilution of 1:200. Alkaline phosphatase–
labeled goat anti-mouse IgG (Southern Biotechnology)
served as second antibody. A high titer–positive MRL/
lpr serum served as standard.
Total levels of IgG1 and IgG2a were measured by
sandwich ELISA as previously described [6].
ELISAs for cytokines were performed on culture su-
pernatants of splenocytes using rat mAb pairs for mouse
IFN- and IL-4 (PharMingen, San Diego, CA, USA).
Samples were added undiluted and purified mouse cyto-
kines served as standards (PharMingen). After incuba-
tion with biotinylated rat anti-mouse cytokine-specific
antibodies, 100 L/well of 1:1000 streptavidin-alkaline
phosphatase (Southern Biotechnology) was added, and
the reaction was developed.
Cytokine RT-PCR
Total RNA from freshly isolated splenocytes was pre-
pared by TRIzol Reagent (Invitrogen, Carlsbad, CA,
USA) and mRNA expression for various cytokines was
detected using the ThermoScript reverse transcription-
polymerase chain reaction (RT-PCR) System (Invitro-
gen). For each sample, 1 g of total RNA was reverse
transcribed and control reactions lacking reverse tran-
scriptase were carried out to exclude contamination with
genomic DNA. Amplification of cDNA was carried out
in a thermocycler with 0.5 units of Taq DNA polymerase
in a 20 L reaction. Amplification conditions were 94C
for 1 minute, 60C for 1 minute, 72C for 1.5 minutes,
and 72C for 10 minutes as the final extension. Cycle
numbers were optimized for each primer pair. PCR prod-
ucts were analyzed on 3% agarose gels and visualized
by ethidium bromide staining. Primer sequences were
as follows: mouse IL-12p35 sense (5-GCAAGAGACA
CAGTCCTGGG-3), antisense (5-TGCATCAGCTC
ATCGATGGC-3), yielding a PCR product of 617 bp;
mouse IL-12p40 sense (5-GAGGTGGACTGGACTC
CCGA-3), antisense (5-CAAGTTCTTGGGCGGGT
CTG-3), yielding a product of 617 bp; mouse IL-4 sense
(5-CGAAGAACACCACAGAGAGTGAGCT-3), anti-
Calvani et al: IL-12 in pristane-induced lupus 899
Table 1. Renal lesions in BALB/cJ mice 10 months after treatment (% of mice positive)
N IgG1a IgG2aa IgG2ba IgG3a IgMa C3a Capb LMc Proteinuriad
/ Pristane 28 50 64 21 46 25 68 25 29 29
/ PBS 13 0 0 0 0 0 0 0 0 0
IL-12 / Pristane 20 45 45 35 70 10 40 5 0e 0e
IL-12 / PBS 5 0 0 0 0 0 0 0 0 0
PBS is phosphate-buffered saline.
a Positive glomerular immunofluorescence on frozen sections for IgG1, IgG2a, IgG2b, IgG3, IgM, or C3
b Presence of staining in a capillary pattern
c Presence of light microscopy proliferative changes by periodic acid-Schiff
d Only values 3 (300 mg/dL) at 10 months were considered elevated
e P 	 0.05 vs. / pristane-treated mice (Fisher exact test)
sense (5-GACTCATTCATGGTGCAGCTTATCG-3),
yielding a 180 bp product; mouse IFN- sense (5-AGC
GGCTGACTGAACTCAGATTGTAG-3) antisense
(5-GTCACAGTTTTCAGCTGTATAGGG-3), yield
ing a PCR product of 246 bp; mouse IL-1 8 sense
(5-ACTGTACAACCGCAGTAATACGG-3) antisense
(5-TCCATCTTGTTGTGTCCTGG-3), yielding a 319
bp product. Each reverse transcribed mRNA was inter-
nally controlled with 
-actin using the primers mouse
sense (5-TGGAATCCTGTGGCATCCATGAAAC-3)
and antisense (5-TAAAACGCAGCTCAGTAACAG
TCCG-3), yielding a PCR fragment of 348 bp.
Indirect IF
The Crithidia luciliae assay (The Binding Site, Bir-
mingham, UK) was used to analyze sera (1:20 dilution)
for anti-ds DNA. The second antibody was FITC-conju-
gated goat anti-mouse IgG (1:60 dilution; Southern Bio-
technology).
Statistical analysis
Frequencies of renal lesions and autoantibodies were
compared by Fisher exact test. Mann-Whitney test was
used to compare levels of autoantibodies and cytokines.
RESULTS
Pristane treatment induces nephritis and production of
autoantibodies associated with SLE in non-autoimmune
mice [18]. Development of nephritis and production of
certain autoantibodies is IFN- dependent not only in
pristane-induced lupus [6] but also in MRL/lpr [4, 5, 19]
and NZB/W mice [20], suggesting that lupus-like disease
is Th1 driven. IL-12 is one of the most powerful inducers
of a Th1 immune response. In this study, we investigated
the role of this cytokine for the pathogenesis of lupus-
like disease induced by the hydrocarbon oil pristane.
IL-12 is essential for the development of
pristane-induced nephritis
The effect of IL-12 on pristane-induced nephritis was
examined 10 months after treatment. This time point was
chosen to ensure that all mice originally entered into the
study were still alive. In previous experiments we found
that some BALB/c / mice can die of nephritis after
10 months. As expected, pristane induced diffuse prolif-
erative glomerulonephritis in about one third of /
mice, all of which also had proteinuria (Table 1, Fig. 1).
In contrast to this, none of pristane-treated IL-12 /
mice had LM changes (Table 1, Fig. 1), and none of
these mice developed significant proteinuria (Table 1). Sur-
prisingly, immune complex deposition was similar in
both / and IL-12 / mice and, although capillary
staining was more common in / mice (Table 1, Fig. 1),
this difference was not statistically significant. Mice with
staining for IgG commonly were positive for all IgG
subclasses and had C3 deposits. No LM changes or im-
mune deposits were seen in any of the PBS-treated mice
(Table 1, Fig. 1). Tubulo-interstitial pathology was not
present in either pristane- or PBS-treated mice in any
group.
IL-12 is not required for the induction of
nephritogenic autoantibodies
The absence of IL-12 did not affect the production of
nephritogenic autoantibodies, and there was no statisti-
cally significant difference in frequency of both IgG anti-
dsDNA and anti-chromatin between pristane-treated
IL-12/ and/mice after 6 months (Table 2). Unex-
pectedly, anti-dsDNA was found more commonly in
IL-12 / mice (Fig. 2). To confirm this result we com-
pared the measurement of anti-dsDNA by ELISA with
the Crithidia luciliae assay for all samples (Table 2, Fig. 2).
Anti-dsDNA ELISA is generally less specific and tends
to produce more false-positive results, whereas the Crith-
idia assay has higher specificity [21]. We found that by
either method there was no significant difference in pris-
tane-induced anti-dsDNA between IL-12 / and /
mice (Fig. 2). Although the frequency of anti-chromatin
antibodies was similar in both groups of mice, the onset
of anti-chromatin production may have been somewhat
delayed in pristane-treated IL-12/ mice (Fig. 3).
In contrast to the effect on anti-dsDNA and chroma-
tin, pristane induced production of IgG anti-nRNP auto-
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Fig. 1. Light microscopy (LM) and direct immunofluorescence (IF). Renal tissue was obtained from mice 10 months after treatment and fixed in
4% paraformaldehyde. Sections (3 m) were stained with periodic acid-Schiff (PAS) for LM. Unfixed frozen sections were stained by direct IF
with fluoroscein isothiocyanate (FITC)-conjugated goat anti-mouse immunoglobulin (Ig) G2a. Photomicrographs were taken using a 40 lens for
all samples. (A) Pristane-treated / mice with extensive endocapillary and mesangial hypercellularity, leukocyte infiltration, and thickening of the
capillary walls. (B) Phosphate-buffered saline (PBS)-treated / mice with normal glomeruli. (C) pristane-treated IL-12 / mice with normal
glomerulus, (D) PBS-treated IL-12 / mice with normal glomerulus, (E) pristane-treated / mice with marked capillary IgG2a deposits, (F)
PBS-treated / mice without staining for IgG2a, (G) pristane-treated IL-12 / mice with mesangial IgG2a deposits, (H) PBS-treated IL-12 /
mice with no significant staining for IgG2a.
antibodies in 80% of / mice at 6 months versus 21%
in IL-12 / mice (P 	 0.05, Fisher exact test) (Table 2).
Moreover, levels of IgG anti-nRNP/Sm were dramati-
cally lower in pristane-treated IL-12/mice compared
to pristane-treated / mice (P 	 0.05, Mann-Whitney
test) (Fig. 4, left). Frequencies of IgG anti-Su (immu-
noprecipitation assay) were similar in pristane-treated
IL-12/ and/mice (Table 2). Spontaneous produc-
tion of IgG anti-nRNP/Sm was not observed by ELISA
(data not shown) or immunoprecipitation (Fig. 4, right)
in PBS-treated mice.
Pristane-induced hypergammaglobulinemia is reduced
in IL-12 / mice
Given the association of pristane-induced lupus with
marked hypergammaglobulinemia [22], it was of interest
to examine the influence of IL-12 deficiency on total IgG
production. As expected, pristane-treated/mice had
elevated IgG1 and IgG2a levels by 6 months after treat-
ment when compared with PBS-treated/mice (Fig. 5).
Pristane-induced hypergammaglobulinemia was signifi-
cantly reduced in IL-12 / mice with lower levels of
both total IgG1 and IgG2a versus / mice (P 	 0.05,
Mann-Whitney test) (Fig. 5).
Cytokine production
Levels of IFN- and IL-4 were examined in spleno-
cyte culture supernatants after 10 months of treatment
Table 2. Frequencies of autoantibodies in BALB/cJ mice 6 months
after treatment
/ IL-12 /
Pristane PBS Pristane PBS
(N  15) (N  6) (N  14) (N  5)
Anti-chromatin 80% 0% 57% 0%
Anti-dsDNAa 14% 0% 43% 0%
Anti-nRNP/Sm 80% 0% 21%b 0%
Anti-Su 26% 0% 21% 0%
PBS is phosphate-buffered saline. Note: serum was not available for all mice.
a Measured by crithidia assay
b P 	 0.05 vs. pristane treated / mice (Fisher exact test)
(Fig. 6A). IFN- production was similar in PBS-treated
IL-12 / mice and PBS-treated / mice, confirming
that IL-12/mice are not devoid of IFN- production
[12]. Pristane treatment enhanced IFN- expression in
/ mice, whereas IFN- levels remained unchanged in
IL-12/mice. In contrast, pristane markedly enhanced
IL-4 production in IL-12 / mice compared to PBS-
treated IL-12 / (P 	 0.05, Mann-Whitney test) and
pristane-treated/mice. We also examined expression
of key cytokines of interest by RT-PCR on RNA from
splenocytes (Fig. 6B). Pristane preferentially induced
IL-4 expression in IL-12/ mice, whereas both IFN-
and IL-18 expression were similar in all groups. IL-12p40
appeared to be up-regulated by pristane in both groups.
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Fig. 2. Immunoglobulin G (IgG) anti-dsDNA. Sera from mice ob-
tained 6 months after treatment were analyzed for IgG anti-dsDNA
by enzyme-linked immunosorbent assay (ELISA). Results are shown
in optical density (OD). Horizontal lines indicate the mean levels in
each group. Levels of anti-dsDNA are not different in pristane-treated
IL-12 / mice and / mice after 6 months of treatment. Samples
that were also positive for anti-dsDNA by Crithidia luciliae assay are
denoted by an asterisk.
Absence of IL-12p35 message in the targeted mutants
was also demonstrated (Fig. 6B). These data confirm
that cytokine balance is fundamentally skewed toward
a Th2 response in pristane-treated IL-12 / mice.
DISCUSSION
Study of the pathogenesis of SLE has led to growing
appreciation of the complex role of cytokines in the
regulation of autoimmune renal injury in SLE. It has
become evident that alteration in cytokine milieu is a
common feature, both in human and experimental lupus.
Although LN has been thought to be Th2 mediated
[23, 24], there is now strong evidence linking Th1 cyto-
kine production to induction of nephritogenic autoanti-
bodies and renal disease [3, 5, 19, 20]. Adding to this
evidence we recently reported that IFN- / mice are
resistant to LN after pristane treatment, whereas the
absence of IL-4 has no influence on the development of
renal disease [6].
IL-12 directs the differentiation of naı¨ve T lympho-
cytes toward Th1 cells by inducing IFN- [25] and inhib-
iting the development of IL-4–producing Th2 cells [26].
The role of IL-12 in the pathogenesis of SLE remains
unclear. It has been proposed that a defect in IL-12
production by macrophages is essential for disease in
lupus-prone MRL and NZB/W mice [8]. Down-regula-
tion of IL-12 is thought to reflect increased disease activ-
ity of SLE in humans [9] and is believed to be related
to the development of LN [10]. In contrast to these
findings others have reported significant elevations of
serum IL-12 levels in MRL/lpr mice and found that re-
combinant IL-12 injection leads to accelerated glomeru-
Fig. 3. Immunoglobulin G (IgG) anti-chromatin autoantibodies. Sera
from mice obtained before treatment, at 0.5 months, and monthly there-
after were analyzed for anti-chromatin by enzyme-linked immunosor-
bent assay (ELISA). Results are shown in units.
lonephritis [27]. Moreover, it has been suggested that
IL-12 plays a key role in the pathogenesis of autoimmune
disease in MRL/lpr mice by promoting the differentia-
tion of CD4 T cells into Th1 cells [28].
Pristane-induced LN is IL-12 dependent
Our results indicate that IL-12p35 is essential for the
development of structural renal damage in pristane-
induced LN. None of the 20 pristane-treated IL-12 /
animals showed changes in glomerular morphology, and
proteinuria was absent (Table 1). This was the case de-
spite a similar degree of immune complex deposition in
both IL-12 / and / mice. However, glomerular
immune deposits in IL-12 / mice were mostly in a
mesangial pattern (Fig. 1), whereas capillary deposits
were seen more frequently in the / group (Fig. 1),
suggesting the presence of subepithelial and/or subendo-
thelial deposits as shown previously [18]. Particularly,
the subendothelial immune deposits may be a prerequi-
site for the development of proliferative glomerular pa-
thology.
Our data further underscore the importance of Th1
responses for pristane-induced LN [6], as pristane treat-
ment enhanced IFN- expression in / mice (Fig. 6).
Interestingly, IL-12 / mice were not devoid of IFN-
production (Fig. 6, PBS-treated IL-12/ group), prob-
ably due to IL-18 production [29]. IFN- levels remained
unchanged after pristane treatment. It is perhaps note-
worthy that despite significant levels of IFN- RNA at
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Fig. 4. Immunoglobulin G (IgG) anti-nRNP/Sm
autoantibodies. Sera from mice obtained before
treatment, at 0.5 months, and monthly thereafter
were analyzed for IgG anti-nRNP/Sm by en-
zyme-linked immunosorbent assay (ELISA)
(left). Results are shown in units. Phosphate-
buffered saline (PBS)-treated mice did not pro-
duce anti-nRNP/Sm and are not shown. Sera
obtained 6 months after treatment were ana-
lyzed by immunoprecipitation. Representative
samples are shown (right). Lane 1 shows a ref-
erence serum immunoprecipitating the charac-
teristic bands for anti-nRNP/Sm (A, B/B, C,
D, EF, and G) and the characteristic 110 kD
band for anti-Su. Lanes 2, 3, 6, and 7 show
bands for anti-nRNP/Sm, and lanes 6 and 7 are
positive for anti-Su.
Fig. 5. Total immunoglobulin (Ig) levels. Sera from mice obtained before treatment, at 0.5 months, and monthly thereafter were analyzed for
IgG1 and IgG2a by enzyme-linked immunosorbent assay (ELISA). Results are shown in mg/mL.
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Fig. 6. Cytokine production. (A ) Splenocytes
from 10-month-old mice were cultured for 48
hours in the presence of 2 g/mL anti-CD3.
Supernatants were removed and activity of in-
terferon- (IFN-) and interleukin-4 (IL-4)
was analyzed by enzyme-linked immunosor-
bent assay (ELISA). Median values are shown
in ng/mL. (B ) Total RNA was extracted from
freshly isolated splenocytes and cytokine ex-
pression was analyzed by reverse transcription-
polymerase chain reaction (RT-PCR). 
-actin
served as control.
baseline (Fig. 6B), production of the protein was only
minimally enhanced following anti-CD3 stimulation
(Fig. 6A). This points toward the requirement for both
IL-12 and IL-18 to synergistically promote IFN- pro-
duction. Also of interest was the increased level of
IL-12p40 RNA following pristine treatment in both and
IL-12p35/ and/ mice. This suggests that pristane
may have an effect on either the transcriptional rate
of p40 mRNA or on its stability. In contrast, pristane
enhanced IL-4 production in IL-12 / mice (Fig. 6),
suggesting that a Th2-skewed cytokine profile in the ab-
sence of IL-12 may possibly prevent the onset of LN.
This amelioration of nephritis may have therapeutic im-
plications.
In favor of an involvement of IL-12 in murine lupus–
related renal disease, it has been reported that intrarenal
IL-12 production is up-regulated in MRL/lpr mice, lead-
ing to enhanced IFN- expression and promoting the
development of a renal-specific Th1 immune response
[30]. In addition, local provision of IL-12 using an ex vivo
retroviral gene transfer strategy enhances renal damage
by fostering the expansion of IFN-–secreting CD4 T
cells within the kidney in MRL/lpr mice [31]. The role
of IL-12 in human SLE remains controversial. Decreased
production of this cytokine was reported in stimulated
lymphocytes from 10 patients with recent-onset active
lupus, 9 of who had renal involvement [9]. Another group
reported decreased IL-12 and IFN- but increased IL-4
and IL-10 in stimulated peripheral blood mononuclear
cells [10]. There were no differences in serum IL-12
levels between normal patients and patients with SLE.
In contrast to this, others have found high serum levels
of IL-12 and IFN- in SLE patients, but no significant
correlation with the presence of nephritis [32]. These
discrepancies may reflect the heterogeneity of the disease
or the differences in racial composition of the study pop-
ulation. Further confounding the interpretation of these
studies, stimulatory effects of peripheral blood mononu-
clear cells (PBMC) separation on lymphocytes [33], and
the presence of rheumatoid factors in the sera of patients
with SLE [34] may directly interfere with the cytokine
assays used in the above studies. Future studies exploring
the roles of IL-12 and IFN- in human LN seem war-
ranted. Until such studies become available it will remain
unclear whether human LN, like murine LN, is mediated
by Th1 cytokines or whether the pathogenesis of the
disease is different in humans and mice.
Lack of relationship between nephritogenic antibodies,
immune complex deposition, and structural renal damage
Elevated anti-dsDNA levels with a corresponding de-
pression of total hemolytic complement mark active ne-
phritis [35, 36]. Similarly anti-chromatin antibodies have
been linked to LN [1]. However, the pathogenic rele-
vance of these antibodies is much debated and it has been
suggested that the presence of such antibodies alone is
not sufficient for the development of nephritis. Indeed,
nephritis in the absence of anti-DNA autoantibodies is
seen in both murine and human lupus [37–39]. Glomeru-
lar deposits of immunoglobulins and complement com-
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ponents are a hallmark of LN. Nevertheless, there is
evidence that the presence of certain mediators, such as
Fc receptors, is required for the pathogenic effects of
such deposits.
Our results support the idea that the presence of im-
mune deposits and nephritogenic antibodies is insuffi-
cient to lead to nephritis. We speculate that either local
effects of IL-12 itself, or effects mediated through IFN-,
are required for the development of renal tissue damage.
The latter is known to enhance cell adhesion molecule
expression on glomerular cells [40], which in turn may
facilitate influx of inflammatory cells. Alternatively, the
slightly altered isotype distribution of the glomerular im-
mune deposits brought about by lack of IL-12 (Table 1),
leading to decreased Fc receptor triggering, may explain
the lack of proliferative disease in IL-12 / mice. It is
further possible that the relative predominance of Th2
cytokines and/or of Th2 T cells in IL-12/mice down-
modulates the inflammatory response in the kidney.
CONCLUSION
We have established that IL-12 is essential for the
development of pristane-induced nephritis, whereas im-
mune complex deposits and nephritogenic autoantibod-
ies are independent of IL-12. Pristane-induced anti-
nRNP/Sm is, in turn, IL-12–dependent. Future studies
are needed to determine the relevance of these observa-
tions to human LN. Presently available information im-
plicates Th1 cytokines in murine disease and Th2 cyto-
kines in human disease. It will be important to know if
this represents a fundamental difference between the
pathogenesis of human and murine lupus, or only an
apparent dichotomy.
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